NT5E and colitis: In this study, CD73-expressing ERCs-based therapy significantly ameliorated the signs of DSS-induced colitis, including body weight loss, shortened colon length, hematochezia, and pathological scoring in mice; the finding is in accordance with the report from our previous studies (71).